UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549
--------------------------------------------------------------------------------


                                    FORM 8-K

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE

                         SECURITIES EXCHANGE ACT OF 1934



Date of report (Date of earliest event reported):  December 12, 2003
                                                   -----------------


                         BIO-IMAGING TECHNOLOGIES, INC.
                         ------------------------------
               (Exact Name of Registrant as Specified in Charter)


         Delaware                       1-11182                 11-2872047
--------------------------------------------------------------------------------
(State or Other Jurisdiction    (Commission File Number)       (IRS Employer
    of Incorporation)                                        Identification No.)



826 Newtown-Yardley Road, Newtown, PA                                   18940
--------------------------------------------------------------------------------
(Address of Principal Executive Offices)                              (Zip Code)


                                 (267) 757-3000
                                 --------------
                         (Registrant's telephone number,
                              including area code)



          -------------------------------------------------------------
          (Former Name or Former Address, if Changed Since Last Report)






ITEM 5. OTHER EVENTS AND REQUIRED FD DISCLOSURE.

     On December  12,  2003,  Bio-Imaging  Technologies,  Inc.  (the  "Company")
announced  that its common  stock,  $0.00025  par value,  has been  approved for
quotation on the Nasdaq National Market.  Trading is expected to commence at the
opening of the market on December 18, 2003, under the symbol "BITI".

     The  full  text  of  the  press  release  issued  in  connection  with  the
announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.


ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.

     (c) Exhibits.

         Exhibit No.                      Description of Exhibit
         -----------                      ----------------------

            99.1                          Press release dated December 12, 2003.







                                      -2-



                                    SIGNATURE


     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.



                               BIO-IMAGING TECHNOLOGIES, INC.



Dated: December 12, 2003       By:  /s/ Mark L. Weinstein
                                  ----------------------------------------------
                                  Name:  Mark L. Weinstein
                                  Title: President and Chief Executive Officer







                                  EXHIBIT INDEX



Exhibit No.                    Description
-----------                    -----------

99.1                           Press release dated December 12, 2003.